Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Hansoh BioMedical R&D Company
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07645222CT.gov PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC | — | Not Yet Recruiting | — | — | — |
NCT04841811CT.gov MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) | — | Active Not Recruiting | — | — | — |
NCT05826483CT.gov Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status | — | Unknown | — | — | — |
NCT04882345CT.gov Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment | — | Unknown | — | — | — |
NCT04808752CT.gov Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases | — | Unknown | — | — | — |
NCT04884009CT.gov A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Famitinib (this asset) | Hansoh BioMedical R&D Company | P3 | B · 60 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Famitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P3 | BB · 68 |
| Breast Carcinoma | — | P3 | BB · 66 |
| Non-Small Cell Lung Carcinoma | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Famitinib in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/famitinib-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →